

# Appendix 3Y

## Change of Director's Interest Notice

<b>Name of entity</b>	<b>Impression Healthcare Limited</b>
<b>ACN</b>	<b>93 096 635 246</b>

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

<b>Name of Director</b>	Joel LATHAM
<b>Date of last notice</b>	26 August 2019

### Part 1 - Change of director's relevant interests in securities

<b>Direct or indirect interest</b>	Direct
<b>Nature of indirect interest</b>	n/a
<b>Date of change</b>	3 September 2019
<b>No. and class of securities held prior to change</b>	<ul style="list-style-type: none"> <li>10,245,795 IHL ordinary shares</li> <li>4,237,500 IHLOB options</li> <li>6,000,000 unlisted performance rights</li> <li>200,000 unlisted \$0.08 Options expiry 30-Sep-21</li> </ul>
<b>Number and class of securities acquired</b>	1,750,000 restricted IHL fully paid shares (escrowed); and 2,250,000 restricted unlisted \$0.08 Options expiry 03-Sep-27 (escrowed)
<b>Number and class of securities disposed</b>	Nil
<b>Value/Consideration</b>	Nil
<b>No. of securities held after change</b>	<ul style="list-style-type: none"> <li>10,245,795 IHL ordinary shares</li> <li>4,237,500 IHLOB options</li> <li>6,000,000 unlisted performance rights</li> <li>200,000 unlisted \$0.08 Options expiry 30-Sep-21</li> <li>1,750,000 restricted IHL fully paid shares (escrowed)</li> <li>2,250,000 restricted unlisted \$0.08 Options expiry 03-Sep-27 (escrowed)</li> </ul>
<b>Nature of change</b>	Part of CEO/MD revised employment remuneration terms

### Part 2 – Change of director's interests in contracts

In addition to the above issue of securities the Board has set the CEO/MD base salary at \$180,000 for FY20 with the amount of \$30,000 per annum also payable as director's fee from the date of appointment as MD. These amounts are exclusive of statutory superannuation entitlements and the CEO/MD also has ability to receive a further 50% of base salary (\$90,000) upon achievement of performance milestones and evaluation of CEO/MD performance by the Board at the completion of the financial year.

### Part 3 – Closed period

<b>Were the interests in the securities or contracts detailed above traded during a closed period where prior written clearance was required?</b>	No
<b>If so, was prior written clearance provided to allow the trade to proceed during this period?</b>	N/a
<b>If prior written clearance was provided, on what date was this provided?</b>	N/a